CPHA Canvax

"Au Québec, le vaccin pneumococcique conjugué 10-valent (VPC-10) a remplacé le vaccin 13-valent (VPC-13) au cours de l’année 2018 pour l’immunisation des enfants ayant un risque d’infection invasive à pneumocoque faible ou modéré. Le plus faible coût du VPC-10 a été un élément important dans la décision." - Évaluation de la pertinence d’utiliser le vaccin pneumococcique conjugué 13 valent plutôt que 10-valent dans une perspective économique au Québec

Rating See Comments Ratings

Category:

Policy,Immunization Policies,Cost Effectiveness,Vaccine Preventable Diseases,Communicable Diseases,Pneumococcal Disease Policy
Immunization Policies
Cost Effectiveness
Vaccine Preventable Diseases
Communicable Diseases
Pneumococcal Disease

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.